Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Patient Satisfaction 2Urologic Neoplasms 1Thyroid Cancer, Papillary 1Sarcoma, Ewing 1Sarcoma 1Radiation Injuries 1Patient Preference 1Patient Acceptance of Health Care 1Osteosarcoma 1Osteitis Deformans 1Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Gemcitabine 7Doxorubicin 4Cyclophosphamide 4pembrolizumab 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cisplatin 3regorafenib 2Vincristine 2Tranexamic Acid 2Sunitinib 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Radiation 2Proton Therapy 2Nivolumab 2Methotrexate 2Methods 2Interviews as Topic 2Indocyanine Green 2Everolimus 2Curettage 2Ascorbic Acid 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tocilizumab 1samarium Sm-153 lexidronam 1poly ICLC 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bone Neoplasms × delta 24-sterol reductase × Clear all
NCT01882231 2017-05-08

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
6 enrolled
Sarcoma

Bone Neoplasms, Osteitis Deformans, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡